Analysts Predict 11% Growth Potential for IWS Holdings
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 22 2025
0mins
Should l Buy MRNA?
Source: NASDAQ.COM
ETF Analysis: The iShares Russell Mid-Cap Value ETF (IWS) has an implied analyst target price of $153.61, indicating a potential upside of 10.74% from its current trading price of $138.72.
Notable Holdings: Key underlying holdings with significant upside potential include Viking Therapeutics (VKTX), Moderna (MRNA), and Civitas Resources (CIVI), with expected target price increases of 251.09%, 65.65%, and 37.99%, respectively.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MRNA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MRNA
Wall Street analysts forecast MRNA stock price to fall
20 Analyst Rating
1 Buy
16 Hold
3 Sell
Hold
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
Current: 49.830
Low
17.00
Averages
32.47
High
63.00
About MRNA
Moderna, Inc. is a biotechnology company. The Company is advancing a new class of medicines made of messenger ribonucleic acid (mRNA). It is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and autoimmune diseases. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that have a therapeutic or preventive benefit with the potential to address a spectrum of diseases. The Company’s diverse development pipeline consists of 44 therapeutic and vaccine programs, 11 of which are in late-stage development. Its commercial products include Spikevax (its COVID vaccine) and mRESVIA (its respiratory syncytial virus (RSV) vaccine). Additionally, it has achieved four positive Phase III data readouts for its COVID vaccine (mRNA-1283), its RSV vaccine for high-risk adults aged 18 to 59 (mRNA-1345), its seasonal flu+COVID vaccine (mRNA-1083), and its seasonal flu vaccine (mRNA-1010).
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
Wall Street Rallies on Optimism Over US-Iran Diplomatic Talks
- Market Rally: Wall Street experienced a relief rally on Wednesday, driven by optimism surrounding potential US-Iran diplomatic talks, with the Nasdaq 100 gaining 1.5% to 25,100, indicating investor confidence in future economic stability.
- Oil Price Decline: Following two consecutive days of gains, Brent crude fell 0.5% to $81.00 per barrel and WTI crude slipped 0.8% to $74.07, reflecting the impact of diplomatic optimism on the energy market.
- Volatility Index Drop: The CBOE Volatility Index plunged 11.6% to 20.84, indicating a rise in market risk appetite and a decrease in demand for safe-haven assets, further fueling the stock market's upward momentum.
- Stable Treasury Yields: The 10-year U.S. Treasury yield held steady at 4.07%, suggesting that as risk appetite increases, demand for safe assets is capped, reflecting a positive outlook on economic prospects.
See More
US Stocks Fluctuate Slightly Amid Oil Price Pressures
- Market Movements: The S&P 500 Index rose by 0.03%, while the Dow Jones Industrial Average fell by 0.11%, and the Nasdaq 100 Index increased by 0.63%, reflecting a slight recovery in the market following reports of indirect contact between Iran and the US to negotiate an end to the conflict, despite ongoing global trade tensions.
- Employment Data Impact: The February ADP employment report indicated an increase of 63,000 jobs, surpassing expectations of 50,000, suggesting a resilient labor market that may support the stock market, while also raising concerns about Federal Reserve policy direction.
- Oil Price Fluctuations: Crude oil prices fell by over 1% after Iran proposed discussions with the US to end the conflict, compounded by Treasury Secretary's comments on potential 15% tariffs on imports, adding to market uncertainty.
- Economic Outlook: This week, the market will focus on US-Iran war news, corporate earnings, and economic data, with expectations for a slight decline in the February ISM services index and an increase of 3,000 in initial unemployment claims to 215,000, highlighting the complexities of economic recovery.
See More
Erie Indemnity Shares Drop 3.2% Today
- Poor Stock Performance: Erie Indemnity's shares are down 3.2% today, making it the worst performer in the S&P 500, indicating market concerns about its future outlook.
- Year-to-Date Review: Year-to-date, Erie Indemnity has declined approximately 8.1%, highlighting its vulnerability in the overall market environment, which may affect investor confidence.
- Other Component Movements: In contrast, Lennox International's stock is down 2.5%, while Moderna's shares are up 6.9%, reflecting varying market reactions to different companies that could influence portfolio allocation strategies.
- Market Sentiment Analysis: Today's market fluctuations reflect a cautious investor sentiment regarding economic prospects, especially amid increasing uncertainties, potentially leading to more capital outflows from underperforming stocks.
See More
Latham Group Shares Surge After Strong Q4 Results
- Strong Earnings Report: Latham Group reported a fourth-quarter loss of 6 cents per share, outperforming analyst expectations of a 10-cent loss, indicating improvements in cost control and operational efficiency.
- Sales Exceed Expectations: The company achieved quarterly sales of $99.950 million, surpassing the analyst consensus estimate of $96.786 million, reflecting strong market demand and robust product performance, which bolstered investor confidence.
- Significant Stock Surge: Following the positive earnings report, Latham Group's shares jumped 25.7% to $8.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Positive Future Outlook: Latham Group issued FY26 sales guidance above estimates, further solidifying investor confidence in the company's long-term growth trajectory.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
US Stocks Rise on Economic Strength Amid Iran War Concerns
- Strong Economic Data: The February ADP employment report revealed an addition of 63,000 jobs, surpassing expectations of 50,000, indicating continued growth in the labor market and bolstering investor confidence in economic recovery.
- Service Sector Expansion: The US services index unexpectedly rose to 56.1, marking the fastest expansion in 3.5 years, while service price pressures fell to an 11-month low, demonstrating economic resilience that could further drive stock market gains.
- International Situation Impact: Reports of Iran making indirect contact with the US to negotiate an end to the war boosted market sentiment, although Iranian media denied the claims, the hope for an early resolution to the conflict remains.
- Oil Price Volatility: Despite crude oil prices being affected by the Iranian drone attack and the closure of the Strait of Hormuz leading to production cuts in Iraq, the market estimates a risk premium of $18 per barrel, reflecting heightened concerns over energy supply.
See More
Wall Street Rallies on Optimism Over US-Iran Diplomatic Talks
- Market Rally: Wall Street experienced a relief rally on Wednesday, driven by optimism surrounding potential US-Iran diplomatic talks, with the Nasdaq 100 gaining 1.5% to 25,100, indicating investor confidence in future economic stability.
- Oil Price Decline: Following two consecutive days of gains, Brent crude fell 0.5% to $81.00 per barrel and WTI crude slipped 0.8% to $74.07, reflecting the impact of diplomatic optimism on the energy market.
- Volatility Index Drop: The CBOE Volatility Index plunged 11.6% to 20.84, indicating a rise in market risk appetite and a decrease in demand for safe-haven assets, further fueling the stock market's upward momentum.
- Stable Treasury Yields: The 10-year U.S. Treasury yield held steady at 4.07%, suggesting that as risk appetite increases, demand for safe assets is capped, reflecting a positive outlook on economic prospects.
See More
US Stocks Fluctuate Slightly Amid Oil Price Pressures
- Market Movements: The S&P 500 Index rose by 0.03%, while the Dow Jones Industrial Average fell by 0.11%, and the Nasdaq 100 Index increased by 0.63%, reflecting a slight recovery in the market following reports of indirect contact between Iran and the US to negotiate an end to the conflict, despite ongoing global trade tensions.
- Employment Data Impact: The February ADP employment report indicated an increase of 63,000 jobs, surpassing expectations of 50,000, suggesting a resilient labor market that may support the stock market, while also raising concerns about Federal Reserve policy direction.
- Oil Price Fluctuations: Crude oil prices fell by over 1% after Iran proposed discussions with the US to end the conflict, compounded by Treasury Secretary's comments on potential 15% tariffs on imports, adding to market uncertainty.
- Economic Outlook: This week, the market will focus on US-Iran war news, corporate earnings, and economic data, with expectations for a slight decline in the February ISM services index and an increase of 3,000 in initial unemployment claims to 215,000, highlighting the complexities of economic recovery.
See More
Erie Indemnity Shares Drop 3.2% Today
- Poor Stock Performance: Erie Indemnity's shares are down 3.2% today, making it the worst performer in the S&P 500, indicating market concerns about its future outlook.
- Year-to-Date Review: Year-to-date, Erie Indemnity has declined approximately 8.1%, highlighting its vulnerability in the overall market environment, which may affect investor confidence.
- Other Component Movements: In contrast, Lennox International's stock is down 2.5%, while Moderna's shares are up 6.9%, reflecting varying market reactions to different companies that could influence portfolio allocation strategies.
- Market Sentiment Analysis: Today's market fluctuations reflect a cautious investor sentiment regarding economic prospects, especially amid increasing uncertainties, potentially leading to more capital outflows from underperforming stocks.
See More
Latham Group Shares Surge After Strong Q4 Results
- Strong Earnings Report: Latham Group reported a fourth-quarter loss of 6 cents per share, outperforming analyst expectations of a 10-cent loss, indicating improvements in cost control and operational efficiency.
- Sales Exceed Expectations: The company achieved quarterly sales of $99.950 million, surpassing the analyst consensus estimate of $96.786 million, reflecting strong market demand and robust product performance, which bolstered investor confidence.
- Significant Stock Surge: Following the positive earnings report, Latham Group's shares jumped 25.7% to $8.10 on Wednesday, reflecting market optimism regarding the company's future growth potential.
- Positive Future Outlook: Latham Group issued FY26 sales guidance above estimates, further solidifying investor confidence in the company's long-term growth trajectory.
See More
Moderna Settles Patent Dispute with Arbutus and Genevant
- Patent Settlement Agreement: Moderna has agreed to pay $950 million to settle a patent dispute with Arbutus Biopharma and Genevant Sciences, removing a significant legal overhang that is expected to boost market confidence in the company.
- Potential Additional Liability: Under the agreement, Moderna may face up to an additional $1.3 billion payment within 90 days depending on the Federal Circuit's ruling, introducing a layer of uncertainty that could impact its future financial performance.
- Positive Analyst Sentiment: Citi analysts believe the deal alleviates negative pressure on the stock, noting that while it is not the best-case scenario, it is better than feared, with William Blair analysts also viewing it as a positive clearing event.
- Reduced Litigation Costs: J.P. Morgan analysts highlight that the maximum $2.3 billion Moderna must pay is significantly lower than the previously estimated $5 billion, demonstrating effective cost control in the settlement that may contribute to the company's future financial stability.
See More
